Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review
- 28 January 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 164 (2), 238-244
- https://doi.org/10.1111/j.1365-2133.2010.09976.x
Abstract
Most of the publications on isotretinoin, pregnancy and compliance with the pregnancy prevention programme (PPP) originate from North America. Information specific for the European situation is very limited. The aim of this study was to identify publications describing the use of isotretinoin in humans and the compliance with the PPP in Europe, a systematic search in Medline and Embase was conducted using the terms 'isotretinoin, pregnancy (and Europe)'. Furthermore, a manual search in publications was performed. A total of 17 publications were identified. Publications consisted of case reports of exposed pregnancies, surveys among dermatologists or pharmacists and database studies evaluating compliance with the PPP. The studies and surveys dealt with groups of patients exposed to isotretinoin before or during pregnancy and/or compliance with the isotretinoin PPP. Where the information was provided, in 6-26% of cases isotretinoin was prescribed in full accordance with the PPP. Pregnancy incidence was seen in 0·2-1·0 per 1000 women of childbearing age using isotretinoin. Between 65% and 87% of these pregnancies were terminated. This review of studies in Europe performed to date shows failures in the implementation of the PPP. Therefore, the isotretinoin PPP must be scrutinized to identify whether new measures should be taken or whether the failures in the implementation need to be corrected. New measures should take into account the definition of the ultimate goal of a PPP and the acceptable burden. In the meantime, stakeholders could make a start with adjustments in the implementation of the PPP by taking responsibility and enhancing the performance by explicit instructions, monitoring the performance and adjusting, if necessary.Keywords
This publication has 15 references indexed in Scilit:
- Aide au bon usage de l’isotrétinoïne en pratique libérale : observatoire prospectif de 1263 patients acnéiquesAnnales de Dermatologie et de Vénéréologie, 2009
- The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicityPreventive Medicine, 2007
- Trends in Adherence to a Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed PregnanciesArchives of Dermatology, 2005
- Isotrétinoïne : suivi de l’application des recommandations des prescriptions chez les femmes en âge de procréerAnnales de Dermatologie et de Vénéréologie, 2005
- Isotretinoin in Denmark - 20 years onJournal of Dermatological Treatment, 2002
- Restriction of the use of drugs with teratogenic properties: Swedish experiences with isotretinoinTeratology, 1999
- The prescription of isotretinoin to women: is every precaution taken?British Journal of Dermatology, 1998
- A Pregnancy-Prevention Program in Women of Childbearing Age Receiving IsotretinoinThe New England Journal of Medicine, 1995
- Retinoic Acid EmbryopathyThe New England Journal of Medicine, 1985
- TERATOGENICITY OF ISOTRETINOINThe Lancet, 1983